NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Apr 23, 2025•8 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast